Get Started
To learn more about how the NanoAssemblr Ignite and Ignite+ can accelerate preclinical drug development, contact a Scientific Specialist.
Contact a Specialist
LNPs maintain consistent size, polydispersity (PDI) and hematocrit expression as production was scaled across the NanoAssemblr platform. A) mRNA encoding Erythropoietin was formulated into LNPs with equivalent size and PDI across all stages of development. B) Erythrocyte production was elevated equivalently in mice treated with Erythropoietin mRNA-LNPs produced across all stages of development.
To learn more about how the NanoAssemblr Ignite and Ignite+ can accelerate preclinical drug development, contact a Scientific Specialist.
Contact a SpecialistPublication - Abstract
September 15, 2021
Vaccine
Publication - Abstract
August 19, 2021
Publication - Abstract
August 11, 2021
Advanced Science
Publication - Abstract
May 13, 2021
Nature Communications
Publication - Abstract
April 20, 2021
ACS Biomaterials Science & Engineering